Research Library — Page 122 | Reta Compare

3563 research articles. Page 122 of 143.

Articles

• Quad-Agonist GLP Drugs for Pre-Diabetes Prevention
• Quad-Agonist GLP Drugs for Severe Insulin Resistance Syndromes
• Quad-Agonist GLP Drugs for Hypothalamic Obesity
• Quad-Agonist GLP Drugs for Lipodystrophy: A Forward-Looking Analysis
• Quad-Agonist GLP Drugs for Metabolic Syndrome
• Exploring Quad-Agonist GLP Drugs and Bone Health: GIP Receptor Considerations
• Quad-Agonist GLP Drugs for Long-Term Weight Maintenance After Bariatric Surgery
• GLP-1 Receptor Mechanism in Multi-Agonist Drugs
• GIP Receptor Mechanism: The Case for Agonism in Quad-Agonists
• Glucagon Receptor Mechanism: Enhancing Energy Expenditure and Reducing Hepatic Fat
• Amylin Receptor Mechanism: Understanding Satiety, Gastric Emptying, and Glucagon Suppression
• FGF21 Pathway Mechanism in Next-Generation Multi-Agonist Obesity Drugs
• Y2 Receptor (PYY) Mechanism in Long-Acting Satiety Drugs
• Mechanism of the GDF15-GFRAL Pathway in Appetite Suppression
• Activin Type II Receptor Blockade for Lean Mass Preservation in Multi-Agonist Therapies
• Receptor Crosstalk in Multi-Agonist Drugs: Exploring Metabolic Synergy
• Bias-Engineered Multi-Agonists: Tuning Beta-Arrestin and G-Protein Pathways
• Timeline for Quad-Agonist GLP Drugs: A Pipeline Outlook
• Phase 1 Quad-Agonists in Clinical Trials
• Preclinical Quad-Agonists Poised for Clinical Development
• Regulatory Path for Quad-Agonist Obesity Drugs at the FDA
• EMA and Quad-Agonist Approvals in Europe: A Pipeline Outlook
• China's Race to Approve Domestic Multi-Agonist GLP Drugs
• Manufacturing Challenges for Quad-Agonist Peptides in Metabolic Drug Development
• The Future of Quad-Agonist GLP Drugs in Compounding Pharmacy